Premature aging syndrome

Summary

Premature aging syndrome (MONDO:0019303) is a disease (an umbrella term covering 8 Mondo subtypes). A subtype of disease by developmental or physiological process — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 8 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	premature aging syndrome
Mondo ID	MONDO:0019303
MeSH	D019588
Orphanet	79389
UMLS	C0231341
MedGen	65416
GARD	0019017
MedDRA	10063493
Is cancer (heuristic)	no

Also known as: premature ageing

Disease family

An umbrella term covering 8 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › premature aging syndrome

Related subtypes (11): psychiatric disorder, metabolic disease, disorder of development or morphogenesis, inflammatory disease, disorder of glycosylation, ulcer disease, mitochondrial disease, sleep disorder, perinatal disease, obstetric disorder, disease by molecular mechanism

Subtypes (8): Flynn-Aird syndrome, acrogeria, premature aging syndrome, Okamoto type, acroosteolysis-keloid-like lesions-premature aging syndrome, progeroid syndrome, de Barsy syndrome, LMNA-related cardiocutaneous progeria syndrome, telomere syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.